RELMADA THERAPEUTICS INC (RLMD) Fundamental Analysis & Valuation

NASDAQ:RLMD • US75955J4022

Current stock price

6.96 USD
+0.58 (+9.09%)
At close:
6.9 USD
-0.06 (-0.86%)
After Hours:

This RLMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. RLMD Profitability Analysis

1.1 Basic Checks

  • In the past year RLMD has reported negative net income.
  • In the past year RLMD has reported a negative cash flow from operations.
  • RLMD had negative earnings in each of the past 5 years.
  • In the past 5 years RLMD always reported negative operating cash flow.
RLMD Yearly Net Income VS EBIT VS OCF VS FCFRLMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • With a Return On Assets value of -61.05%, RLMD is not doing good in the industry: 68.75% of the companies in the same industry are doing better.
  • Looking at the Return On Equity, with a value of -66.33%, RLMD is in line with its industry, outperforming 43.75% of the companies in the same industry.
Industry RankSector Rank
ROA -61.05%
ROE -66.33%
ROIC N/A
ROA(3y)-112.29%
ROA(5y)-99.18%
ROE(3y)-135.74%
ROE(5y)-115.89%
ROIC(3y)N/A
ROIC(5y)N/A
RLMD Yearly ROA, ROE, ROICRLMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 -400

1.3 Margins

  • RLMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RLMD Yearly Profit, Operating, Gross MarginsRLMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. RLMD Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for RLMD has been increased compared to 1 year ago.
  • RLMD has more shares outstanding than it did 5 years ago.
  • RLMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RLMD Yearly Shares OutstandingRLMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
RLMD Yearly Total Debt VS Total AssetsRLMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 26.11 indicates that RLMD is not in any danger for bankruptcy at the moment.
  • RLMD has a better Altman-Z score (26.11) than 92.71% of its industry peers.
  • There is no outstanding debt for RLMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 26.11
ROIC/WACCN/A
WACCN/A
RLMD Yearly LT Debt VS Equity VS FCFRLMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 14.62 indicates that RLMD has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 14.62, RLMD belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
  • RLMD has a Quick Ratio of 14.62. This indicates that RLMD is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of RLMD (14.62) is better than 88.02% of its industry peers.
Industry RankSector Rank
Current Ratio 14.62
Quick Ratio 14.62
RLMD Yearly Current Assets VS Current LiabilitesRLMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. RLMD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 44.53% over the past year.
EPS 1Y (TTM)44.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 10.76% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y51.2%
EPS Next 2Y18.46%
EPS Next 3Y9.7%
EPS Next 5Y10.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RLMD Yearly Revenue VS EstimatesRLMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 2033 200M 400M 600M
RLMD Yearly EPS VS EstimatesRLMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. RLMD Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RLMD. In the last year negative earnings were reported.
  • Also next year RLMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RLMD Price Earnings VS Forward Price EarningsRLMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RLMD Per share dataRLMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.46%
EPS Next 3Y9.7%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RLMD Dividend Analysis

5.1 Amount

  • RLMD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RLMD Fundamentals: All Metrics, Ratios and Statistics

RELMADA THERAPEUTICS INC

NASDAQ:RLMD (3/31/2026, 8:05:21 PM)

After market: 6.9 -0.06 (-0.86%)

6.96

+0.58 (+9.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-19
Earnings (Next)05-11
Inst Owners68.85%
Inst Owner Change509.16%
Ins Owners6.69%
Ins Owner Change30.79%
Market Cap510.38M
Revenue(TTM)N/A
Net Income(TTM)-57.39M
Analysts86.67
Price Target14.62 (110.06%)
Short Float %5.95%
Short Ratio2.16
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-128.31%
Min EPS beat(2)-153.55%
Max EPS beat(2)-103.08%
EPS beat(4)0
Avg EPS beat(4)-89.43%
Min EPS beat(4)-153.55%
Max EPS beat(4)-17.65%
EPS beat(8)3
Avg EPS beat(8)-38.49%
EPS beat(12)7
Avg EPS beat(12)-22.77%
EPS beat(16)8
Avg EPS beat(16)-17.3%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)59.26%
PT rev (3m)43.33%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-8.2%
EPS NY rev (3m)-21.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.9
P/tB 5.9
EV/EBITDA N/A
EPS(TTM)-1.47
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0
BVpS1.18
TBVpS1.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -61.05%
ROE -66.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-112.29%
ROA(5y)-99.18%
ROE(3y)-135.74%
ROE(5y)-115.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.62
Quick Ratio 14.62
Altman-Z 26.11
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.23%
EPS Next Y51.2%
EPS Next 2Y18.46%
EPS Next 3Y9.7%
EPS Next 5Y10.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-154.06%
EBIT Next 3Y-27.51%
EBIT Next 5Y-5.73%
FCF growth 1Y11.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.53%
OCF growth 3YN/A
OCF growth 5YN/A

RELMADA THERAPEUTICS INC / RLMD Fundamental Analysis FAQ

What is the fundamental rating for RLMD stock?

ChartMill assigns a fundamental rating of 3 / 10 to RLMD.


Can you provide the valuation status for RELMADA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to RELMADA THERAPEUTICS INC (RLMD). This can be considered as Overvalued.


Can you provide the profitability details for RELMADA THERAPEUTICS INC?

RELMADA THERAPEUTICS INC (RLMD) has a profitability rating of 0 / 10.


How financially healthy is RELMADA THERAPEUTICS INC?

The financial health rating of RELMADA THERAPEUTICS INC (RLMD) is 8 / 10.


What is the expected EPS growth for RELMADA THERAPEUTICS INC (RLMD) stock?

The Earnings per Share (EPS) of RELMADA THERAPEUTICS INC (RLMD) is expected to grow by 51.2% in the next year.